Volume 20, Issue 8 (August 2022)                   IJRM 2022, 20(8): 643-650 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Seyedoshohadaei F, Abbasi S, Rezaie M, Allahvaisi A, Rezaie M J, Soufizade N et al . Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: A double-blind RCT. IJRM 2022; 20 (8) :643-650
URL: http://ijrm.ssu.ac.ir/article-1-2029-en.html
1- Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran.
2- Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. , s.abbasi@muk.ac.ir
3- Infertility Treatment Center of Besat Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
4- Department of Obstetrics and Gynecology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
5- Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Abstract:   (472 Views)
Background: Myo-inositol is an intracellular mediator which is involved in various aspects of reproduction in women.
Objective: This study aimed to evaluate the impact of Myo-inositol on the outcomes of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles in infertile women.
Materials and Methods: This double-blind randomized controlled trial was conducted on 70 infertile women referred to the Infertility Treatment Center, Besat hospital, Sanandaj, Iran from May 2019 to September 2019 for IVF/ICSI cycles. The participants were randomly divided into 2 intervention (n = 36) and control (n = 34) groups. The intervention group received 2000 mg of Myo-inositol and 200 mcg folic acid twice a day for 2 months and the control group received 200 mcg of folic acid twice a day for 2 months in the IVF/ICSI cycles (from the third day of cycle until the end of the second month). Finally, the number of oocytes, the quality of embryos, and the IVF/ICSI outcomes were compared between the 2 groups.
Results: The mean numbers of oocytes, MII oocytes, and 2 pronuclear embryos were significantly higher in the intervention group than the control group. Also, the clinical pregnancy and live birth rates in the intervention group were significantly higher than in the controls (p = 0.04).
Conclusion: The administration of Myo-inositol may increase clinical pregnancy and live birth rates by increasing the number of total and meiosis II oocytes in infertile women undergoing IVF/ICSI.
Full-Text [PDF 301 kb]   (277 Downloads) |   |   Full-Text (HTML)  (48 Views)  
Type of Study: Original Article | Subject: Fertility & Infertility

References
1. Ashrafi M, Jahanian Sadatmahalleh Sh, Akhoond MR, Ghaffari F, Zolfaghari Z. ICSI outcome in infertile couples with different causes of infertility: A cross-sectional study. Int J Fertil Steril 2013; 7: 88-95.
2. Andersen AN, Goossens V, Gianaroli L, Felberbaum R, de Mouzon J, Nygren KG. Assisted reproductive technology in Europe, 2003: Results generated from European registers by ESHRE. Hum Reprod 2007; 22: 1513-1525. [DOI:10.1093/humrep/dem053] [PMID]
3. Oehninger S, Gosden RG. Should ICSI be the treatment of choice for all cases of in-vitro conception? No, not in light of the scientific data. Hum Reprod 2002; 17: 2237-2242. [DOI:10.1093/humrep/17.9.2237] [PMID]
4. Showell MG, Mackenzie‐Proctor R, Jordan V, Hart RJ. Antioxidants for female subfertility. Cochrane Database Syst Rev 2017; 7: CD007807. [DOI:10.1002/14651858.CD007807.pub3]
5. Irvine RF. A short history of inositol lipids. J Lipid Res 2016; 57: 1987-1994. [DOI:10.1194/jlr.R071712] [PMID] [PMCID]
6. Chhetri DR. Myo-Inositol and its derivatives: Their emerging role in the treatment of human diseases. Front Pharmacol 2019; 10: 1172. [DOI:10.3389/fphar.2019.01172] [PMID] [PMCID]
7. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013; 95: 1811-1827. [DOI:10.1016/j.biochi.2013.05.011] [PMID]
8. Simi G, Genazzani AR, Obino MER, Papini F, Pinelli S, Cela V, et al. Inositol and in vitro fertilization with embryo transfer. Int J Endocrinol 2017; 2017: 5469409. [DOI:10.1155/2017/5469409] [PMID] [PMCID]
9. Whitaker M. Calcium signalling in early embryos. Philos Trans R Soc Lond B Biol Sci 2008; 363: 1401-1418. [DOI:10.1098/rstb.2008.2259] [PMID] [PMCID]
10. Lee B, Yoon SY, Malcuit Ch, Parys JB, Fissore RA. Inositol 1,4,5-trisphosphate receptor 1 degradation in mouse eggs and impact on [Ca2+]i oscillations. J Cell Physiol 2010; 222: 238-247. [DOI:10.1002/jcp.21945] [PMID] [PMCID]
11. Berridge MJ. The inositol trisphosphate/calcium signaling pathway in health and disease. Physiol Rev 2016; 96: 1261-1296. [DOI:10.1152/physrev.00006.2016] [PMID]
12. Machaca Kh. Ca2+ signaling differentiation during oocyte maturation. J Cell Physiol 2007; 213: 331-340. [DOI:10.1002/jcp.21194] [PMID]
13. Goud PT, Goud AP, Leybaert L, Oostveldt PV, Mikoshiba K, Diamond MP, et al. Inositol 1,4,5-trisphosphate receptor function in human oocytes: Calcium responses and oocyte activation-related phenomena induced by photolytic release of InsP3 are blocked by a specific antibody to the type I receptor. Mol Hum Reprod 2002; 8: 912-918. [DOI:10.1093/molehr/8.10.912] [PMID]
14. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PMM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): A systematic review and meta-analysis. Hum Reprod Update 2010; 16: 577-589. [DOI:10.1093/humupd/dmq015] [PMID]
15. Wang Sh, He G, Chen M, Zuo T, Xu W, Liu X. The role of antioxidant enzymes in the ovaries. Oxid Med Cell Longev 2017; 2017: 4371714. [DOI:10.1155/2017/4371714] [PMID] [PMCID]
16. Jiang WD, Wu P, Kuang ShY, Liu Y, Jiang J, Hu K, et al. Myo-inositol prevents copper-induced oxidative damage and changes in antioxidant capacity in various organs and the enterocytes of juvenile Jian carp (Cyprinus carpio var. Jian). Aquat toxicol 2011; 105: 543-551. [DOI:10.1016/j.aquatox.2011.08.012] [PMID]
17. Walters KA. Role of androgens in normal and pathological ovarian function. Reproduction 2015; 149: R193-R218. [DOI:10.1530/REP-14-0517] [PMID]
18. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009; 147: 120-123. [DOI:10.1016/j.ejogrb.2009.09.008] [PMID]
19. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. New Engl J Med 1999; 340: 1314-1320. [DOI:10.1056/NEJM199904293401703] [PMID]
20. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles: A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750-1754. [DOI:10.1016/j.fertnstert.2008.01.088] [PMID]
21. Caprio F, D'Eufemia MD, Trotta C, Campitiello MR, Ianniello R, Mele D, et al. Myo-inositol therapy for poor-responders during IVF: A prospective controlled observational trial. J Ovarian Res 2015; 8: 37. [DOI:10.1186/s13048-015-0167-x] [PMID] [PMCID]
22. Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore) 2017; 96: e8842. [DOI:10.1097/MD.0000000000008842] [PMID] [PMCID]
23. Kofi Arhin S, Zhao Y, Lu XSh, Cherry M, Lu JQ. Effect of micronutrient supplementation on IVF outcomes: A systematic review of the literature. Reprode Biomed Online 2017; 35: 715-722. [DOI:10.1016/j.rbmo.2017.08.018] [PMID]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb